CeriBell, Inc (CBLL) - Total Liabilities
Based on the latest financial reports, CeriBell, Inc (CBLL) has total liabilities worth $40.47 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CBLL cash flow conversion to assess how effectively this company generates cash.
CeriBell, Inc - Total Liabilities Trend (2022–2025)
This chart illustrates how CeriBell, Inc's total liabilities have evolved over time, based on quarterly financial data. Check CeriBell, Inc (CBLL) asset resilience to evaluate the company's liquid asset resilience ratio.
CeriBell, Inc Competitors by Total Liabilities
The table below lists competitors of CeriBell, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Basilea Pharmaceutica AG
SW:BSLN
|
Switzerland | CHF145.69 Million |
|
Fidus Investment Corp
NASDAQ:FDUS
|
USA | $566.71 Million |
|
Salim Ivomas Pratama Tbk
JK:SIMP
|
Indonesia | Rp14.49 Trillion |
|
Jiangsu Jinji Industrial Co Ltd
SHE:300798
|
China | CN¥948.95 Million |
|
Shenzhen Refond Optoelectronics Co Ltd
SHE:300241
|
China | CN¥1.39 Billion |
|
Zhejiang Fuchunjiang Environmental Thermoelectric Co Ltd
SHE:002479
|
China | CN¥3.87 Billion |
|
Zhuhai Port Co Ltd
SHE:000507
|
China | CN¥11.78 Billion |
|
Kossan Rubber Industries Bhd
KLSE:7153
|
Malaysia | RM352.84 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down CeriBell, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CBLL company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CeriBell, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CeriBell, Inc (2022–2025)
The table below shows the annual total liabilities of CeriBell, Inc from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $40.47 Million | +18.16% |
| 2024-12-31 | $34.25 Million | -79.99% |
| 2023-12-31 | $171.17 Million | -0.97% |
| 2022-12-31 | $172.86 Million | -- |
About CeriBell, Inc
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly t… Read more